CN Patent

CN116745291A — N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺

Assigned to AstraZeneca AB · Expires 2023-09-12 · 3y expired

What this patent protects

披露了具有式(I)的结构的化合物及其药学上可接受的盐，其中X 1 、R 1 、R 2 、R 3 、R 4 、R 5 、和R 6 是如说明书中所定义的；包含此类化合物和盐的药物组合物；此类化合物和盐用于治疗或预防脯氨酰内肽酶成纤维细胞活化蛋白(FAP)‑介导的病症的用途；包含此类化合物和盐的试剂盒；以及用于制造此类化合物和盐的方法。式(I)：

USPTO Abstract

披露了具有式(I)的结构的化合物及其药学上可接受的盐，其中X 1 、R 1 、R 2 、R 3 、R 4 、R 5 、和R 6 是如说明书中所定义的；包含此类化合物和盐的药物组合物；此类化合物和盐用于治疗或预防脯氨酰内肽酶成纤维细胞活化蛋白(FAP)‑介导的病症的用途；包含此类化合物和盐的试剂盒；以及用于制造此类化合物和盐的方法。式(I)：

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN116745291A
Jurisdiction: CN
Classification: —
Expires: 2023-09-12
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.